Access to Non-Summary Clinical Trial Data for Research Purposes Under EU Law

AvDaria Kim

Inbunden, Engelska, 2021

Del i serien Munich Studies on Innovation and Competition

1 268 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt över 249 kr.

Fler format och utgåvor

Häftad

1 268 kr

Beskrivning

This book draws a unique perspective on the regulation of access to clinical trial data as a case on research and knowledge externalities. Notwithstanding numerous potential benefits for medical research and public health, many jurisdictions have struggled to ensure access to clinical trial data, even at the level of the trial results.

Produktinformation

Utgivningsdatum:2021-10-20
Mått:155 x 235 x 23 mm
Vikt:647 g
Format:Inbunden
Språk:Engelska
Serie:Munich Studies on Innovation and Competition
Antal sidor:300
Upplaga:21001
Förlag:Springer Nature Switzerland AG
ISBN:9783030867775

Utforska kategorier

Internationell rätt inom Juridik
Hälso- och sjukvårdsrätt inom Juridik
Medicinsk utrustning och medicinska tekniker inom Medicin

Mer om författaren

Daria Kim is senior research fellow at the Max Planck Institute for Competition and Innovation (Munich), where she works on the topics related to the regulation of the data economy and life sciences. Prior to joining Max Planck Institute, she worked as a research associate at the Chinese University of Hong Kong. She holds MA (Indiana University of Pennsylvania), LLM (Munich Intellectual Property Law Center) and Dr. iur. (the University of Augsburg) degrees.

Innehållsförteckning

PART ONE: Setting the Scene.- Introduction.- The Context and the Problem in Focus.- Secondary Analysis of Clinical Trial Data - A Primer.- PART TWO: Analysis de lege lata,- Legal Sources of Control over and Access to Clinical Trial Data under the EU Applicable Framework.- Implications of IPD Disclosure for Statutory Innovation Incentives PART THREE: Analysis de lege ferenda.- Defining the Intervention Logic of Access-To-Data Measures - A Problem Analysis.- Access to Clinical Trial Data as a Case on R&D Externalities - A Theoretical Framework.- IPD as a Research Resource - Exclusively Controlled or Readily Accessible?.- Evaluating Legislative Options.- Final Conclusions and the Outlook.